Table 1.
Characteristics of 14 included studies
| Study | Publication year | Country | Study period | Research subjects | Study design | Data resource | Pazopanib No. | Sunitinib No. | Median age (y) | Pre-treatment | Median FU(m) | SQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motzerb [7] | 2013 | USA | 2008.8–2011.9 | mRCC | RCT, phase III | 14 countries in USA, Europe, Australia and Asia | 557 | 553 | 61/62 | NPT; RDT | 20/20 | 4 |
| Powles [8] | 2012 | UK | 2008–2011 | clear cell mRCC | RCT, phase II | Multi-institution in UK | 34 | 43 | 67/73 | No treatment | NA | 3 |
| Lalani [9] | 2017 | Canada | 2011.1–2015.11 | clear cell mRCC | RS | Canadian Kidney Cancer Information System database | 93 | 577 | 65/64 | NPT | NA | 7 |
| Kim [13] | 2016 | Korea | NA | mRCC with poor risk features | RS | Asan Medical Center | 72 | 100 | 60/57 | IMT; NPT | 14.2/14.2 | 8 |
| Byfield [14] | 2015 | USA | 2009.10–2012.7 | aRCC | RS | Optum Research Database and IMPACT National Benchmarking Database | 84 | 84 | 63/61.5 | RDT; NPT | 6.0/6.0 | 7 |
| Pal [15] | 2017 | USA | 1993.1–2012.12. | aRCC | RS | The Surveillance, Epidemiology and End Results | 89 | 545 | 68.9/68.1a | NPT | NA | 8 |
| Santoni [16] | 2015 | Italy | 2005.1–2013.7 | late-relapse clear-cell mRCC | RS | 21 Italian centers | 21 | 190 | NA | RN | 58.8/58.8 | 8 |
| Vogelzang [17] | 2017 | USA | 2006.1–2014.12 | aRCC | RS | The 100% Medicare database and Part D | 522 | 522 | 74/74.5 | NA | 15.7/15.7 | 9 |
| Hansenb [18] | 2015 | USA | 2008.8–2011.9 | mRCC | RCT, phase III | 14 countries in USA, Europe, Australia and Asia | 450 | 448 | NA | NPT; RDT | 20.0/20.0 | 4 |
| Racsa [19] | 2015 | USA | 2009.11–2012.1 | aRCC | RS | claims data | 90 | 193 | 67.9/68.2a | NA | 12.0/12.0 | 7 |
| Bianconi [20] | 2016 | Italy | NA | mRCC | RS | NA | 19 | 78 | 68/64 | renal surgery | NA | 7 |
| Escudier [21] | 2014 | France | NA | mRCC | RCT, phase IIIb | NA | 86 | 82 | 64/62 | NPT; RDT | NA | 4 |
| Ruiz-Morales [22] | 2016 | Canada | 2005.1–2015.5 | clear cell mRCC | RS | 29 cancer centers in Canada, USA, Australia and so on | 919 | 6519 | 65/62 | NPT; IMT | NA | 8 |
| Kucharczyk [23] | 2017 | USA | 2006.11.-2013.11 | late-relapse clear cell mRCC | RS | A Single Institution in USA | 11 | 4 | NA | NPT | 38.3/38.3 | 6 |
Abbreviations: mRCC: metastatic renal cell carcinoma, aRCC: advanced renal cell carcinoma, NPT: nephrectomy, RDT: radiotherapy, IMT: immunotherapy, RN: radical nephrectomy, RS: retrospective study, RCT: randomized controlled trial, NA: not available, SQ: score (RCT quality according to the Jadad scale and retrospective study quality according to the Newcastle-Ottawa scale)
a Mean;
b Two studies stemmed from one RCT with different aspects of results: one reported anti-tumor efficacy and toxicity; the other reported economic data